Morgan Stanley Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Report). The company's shares opened today at A$38.62.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Bailey is a 4-star analyst with an average return of 17.4% and a 49.02% success rate. Bailey covers the Healthcare sector, focusing on stocks such as CSL, Resmed, and Ansell.
Currently, the analyst consensus on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is a Strong Buy with an average price target of A$44.59.
Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of A$1.29 billion and a net profit of A$365.04 million. In comparison, last year the company earned a revenue of A$1.2 billion and had a net profit of A$300.49 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
25 minutes ago
- Business Insider
Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS)
In a report released yesterday, Uy Ear from Mizuho Securities maintained a Buy rating on Evolus (EOLS – Research Report), with a price target of $25.00. The company's shares closed yesterday at $10.24. Confident Investing Starts Here: Ear covers the Healthcare sector, focusing on stocks such as Evolus, Tectonic Therapeutic, and Arcutis Biotherapeutics. According to TipRanks, Ear has an average return of -3.1% and a 37.56% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolus with a $24.00 average price target, which is a 134.38% upside from current levels. In a report released on May 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $25.00 price target. Based on Evolus' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $68.07 million and a GAAP net loss of $18.89 million. In comparison, last year the company earned a revenue of $59.33 million and had a GAAP net loss of $13.11 million Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, Albert White, a Director at EOLS bought 20,000.00 shares for a total of $189,000.00.
Business Insider
26 minutes ago
- Business Insider
Alexandria Equities (ARE) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Vikram Malhotra reiterated a Buy rating on Alexandria Equities (ARE – Research Report) yesterday and set a price target of $91.00. The company's shares closed yesterday at $73.19. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Malhotra is a 2-star analyst with an average return of 0.6% and a 50.85% success rate. Malhotra covers the Real Estate sector, focusing on stocks such as First Industrial Realty, Alexandria Equities, and Digital Realty. Alexandria Equities has an analyst consensus of Hold, with a price target consensus of $95.14.
Business Insider
an hour ago
- Business Insider
Novavax Stock (NVAX) Gets a Boost from ‘Robust Immune Responses'
Novavax (NVAX) stock jumped on Wednesday after the vaccine maker released results from a Phase 3 clinical trial of its COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine. The initial cohort results from this study included 'robust immune responses' for the CIC and flu vaccine that were comparable to licensed rivals Nuvaxovid and Fluzone HD. Confident Investing Starts Here: Additionally, Novavax noted that the two vaccines were well tolerated. Almost all of the adverse events, greater than 98%, that were experienced by patients were mild or moderate in severity. The trial includes roughly 2,000 patients aged 65 or older. Novavax stated that it will continue to seek partners to further the development of its CIC and stand-alone flu vaccines. The results from this study provide it with the data it needs for discussions with potential partners. NVAX Stock Movement Today While NVAX stock had soared more than 2% in pre-market trading, the company couldn't maintain those gains. As a result, the stock is only up 0.56% as of Wednesday morning. Investors will also note that shares are down 8.83% year-to-date and 54.6% over the past 12 months. The Phase 3 clinical trial data also failed to attract investor interest today. Trading volume was muted at 1.38 million shares, compared to a three-month daily average of roughly 11.29 million units. Is Novavax Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Novavax is Hold, based on one Buy, two Hold, and a single Sell rating over the past three months. With that comes an average NVAX stock price target of $11.25, representing a potential 55.39% upside for the shares. Spark, TipRanks' AI analyst, highlighted 'strong revenue growth and profitability improvements' but warned of 'negative equity and cash flow challenges.'
